The spectrum of therapeutic activity of mepolizumab. (2nd September 2019)

• Record Type: Journal Article
• Authors: Cavaliere, Carlo; Frati, Franco; Ridolo, Erminia; Greco, Antonio; de Vincentiis, Marco; Masieri, Simonetta; Makri, Eleni; Incorvaia, Cristoforo
• Is Part Of: Expert review of clinical immunology. Volume 15:Number 9(2019)
• Page Start: 959
• Page End: 967
• Publication Date: 2019-09-02
• Subjects: Asthma -- chronic rhinosinusitis -- nasal polyps -- eosinophils -- IL-5 -- mepolizumab -- monoclonal antibodies; Clinical immunology -- Periodicals; 616.079
• DOI: 10.1080/1744666X.2019.1656065
• Languages: English
• ISSNs: 1744-666X

Abstract

ABSTRACT: Introduction : The basis of the development of the anti-interleukin-5 monoclonal antibody mepolizumab was the acknowledgment of the crucial importance of this cytokine in promoting eosinophils production, activation, and survival, which is associated with the eosinophilic asthma phenotype, as well as with other disorders characterized by high levels of eosinophils. Areas covered : All the available literature on the outcomes treatment with mepolizumab in eosinophilic disorders are reviewed, including asthma, chronic rhinosinusitis, esophagitis, granulomatosis with polyangiitis, eosinophilic chronic obstructive pulmonary disease, hypereosinophilic syndrome, and allergic bronchopulmonary aspergillosis. Expert opinion : The efficacy of mepolizumab in eosinophilic asthma is clearly demonstrated by a number of controlled trials and by meta-analyses. Among other eosinophilic disorders, controlled trials are available for chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, hypereosinophilic syndrome, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic obstructive pulmonary disease. Allergic bronchopulmonary aspergillosis, as well as other minor eosinophilic disorders, are backed only by case reports and are waiting controlled trials to verify the therapeutic role of mepolizumab.